WO2008155509A3 - Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci - Google Patents

Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci Download PDF

Info

Publication number
WO2008155509A3
WO2008155509A3 PCT/FR2008/051055 FR2008051055W WO2008155509A3 WO 2008155509 A3 WO2008155509 A3 WO 2008155509A3 FR 2008051055 W FR2008051055 W FR 2008051055W WO 2008155509 A3 WO2008155509 A3 WO 2008155509A3
Authority
WO
WIPO (PCT)
Prior art keywords
viia
pharmaceutical composition
composition containing
factor vii
human factor
Prior art date
Application number
PCT/FR2008/051055
Other languages
English (en)
Other versions
WO2008155509A2 (fr
WO2008155509A9 (fr
Inventor
Emmanuel Nony
Sami Chtourou
Nicolas Bihoreau
Original Assignee
Lab Francais Du Fractionnement
Emmanuel Nony
Sami Chtourou
Nicolas Bihoreau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Emmanuel Nony, Sami Chtourou, Nicolas Bihoreau filed Critical Lab Francais Du Fractionnement
Priority to BRPI0813372-7A2A priority Critical patent/BRPI0813372A2/pt
Priority to CN200880024853A priority patent/CN101743017A/zh
Priority to AU2008265021A priority patent/AU2008265021A1/en
Priority to JP2010511707A priority patent/JP2010529848A/ja
Priority to US12/664,733 priority patent/US20110162094A1/en
Priority to CA2691110A priority patent/CA2691110A1/fr
Priority to EP08805990A priority patent/EP2162147A2/fr
Publication of WO2008155509A2 publication Critical patent/WO2008155509A2/fr
Publication of WO2008155509A3 publication Critical patent/WO2008155509A3/fr
Publication of WO2008155509A9 publication Critical patent/WO2008155509A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

L'invention est relative à des facteurs Vll/Vlla modifiés possédant une haute stabilité, à des acides nucléiques codant pour de tels FVII/Vlla modifiés et à des procédés pour leur production.
PCT/FR2008/051055 2007-06-15 2008-06-12 Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci WO2008155509A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0813372-7A2A BRPI0813372A2 (pt) 2007-06-15 2008-06-12 Fator vii/viia humano modificado, ácido nucléico, vetor de expressão, célula transformada por um ácido nucleico, organismo não humano geneticamente modificado, processo de fabricação de um fator vii/viia, composição de fator vii/viia, composição farmacêutica, e, utilização de um fator vii/viia.
CN200880024853A CN101743017A (zh) 2007-06-15 2008-06-12 经修饰的人因子VII/VIIa和包含它的药物组合物
AU2008265021A AU2008265021A1 (en) 2007-06-15 2008-06-12 Modified human factor VII/VIIa and pharmaceutical composition containing same
JP2010511707A JP2010529848A (ja) 2007-06-15 2008-06-12 修飾したヒト因子ＶＩＩ／ＶＩＩａと、それを含む医薬組成物
US12/664,733 US20110162094A1 (en) 2007-06-15 2008-06-12 Modified human factor vii/viia and pharmaceutical composition containing the same
CA2691110A CA2691110A1 (fr) 2007-06-15 2008-06-12 Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci
EP08805990A EP2162147A2 (fr) 2007-06-15 2008-06-12 Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0755775 2007-06-15
FR0755775A FR2917414B1 (fr) 2007-06-15 2007-06-15 Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci

Publications (3)

Publication Number Publication Date
WO2008155509A2 WO2008155509A2 (fr) 2008-12-24
WO2008155509A3 true WO2008155509A3 (fr) 2009-02-19
WO2008155509A9 WO2008155509A9 (fr) 2010-04-08

Family

ID=38702010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/051055 WO2008155509A2 (fr) 2007-06-15 2008-06-12 Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci

Country Status (12)

Country Link
US (1) US20110162094A1 (fr)
EP (1) EP2162147A2 (fr)
JP (1) JP2010529848A (fr)
KR (1) KR20100039281A (fr)
CN (1) CN101743017A (fr)
AR (1) AR067335A1 (fr)
AU (1) AU2008265021A1 (fr)
BR (1) BRPI0813372A2 (fr)
CA (1) CA2691110A1 (fr)
FR (1) FR2917414B1 (fr)
TW (1) TW200906851A (fr)
WO (1) WO2008155509A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (fr) 2011-08-02 2013-02-06 LFB Biotechnologies Composition pharmaceutique comprenant factor VII encapsulé dans des micelles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010295A1 (fr) * 1987-06-25 1988-12-29 Novo-Nordisk A/S FACTEUR VII/VIIa MODIFIE
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
WO2002038162A1 (fr) * 2000-11-09 2002-05-16 The Scripps Research Institute FACTEUR VIIa MODIFIÉ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141646T1 (de) * 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
FR2684999A1 (fr) * 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010295A1 (fr) * 1987-06-25 1988-12-29 Novo-Nordisk A/S FACTEUR VII/VIIa MODIFIE
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
WO2002038162A1 (fr) * 2000-11-09 2002-05-16 The Scripps Research Institute FACTEUR VIIa MODIFIÉ

Also Published As

Publication number Publication date
EP2162147A2 (fr) 2010-03-17
FR2917414A1 (fr) 2008-12-19
WO2008155509A2 (fr) 2008-12-24
FR2917414B1 (fr) 2012-07-13
CN101743017A (zh) 2010-06-16
CA2691110A1 (fr) 2008-12-24
TW200906851A (en) 2009-02-16
KR20100039281A (ko) 2010-04-15
US20110162094A1 (en) 2011-06-30
WO2008155509A9 (fr) 2010-04-08
BRPI0813372A2 (pt) 2014-12-30
JP2010529848A (ja) 2010-09-02
AR067335A1 (es) 2009-10-07
AU2008265021A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
IL220412A0 (en) Antibodies which bind to gm-csf, polynucleotides encoding the same, pharmaceutical compositions containing the same and uses thereof
WO2006131591A3 (fr) Forme posologique destinee a etre administree par voie orale
WO2007139871A3 (fr) Méthodes et matières pour l'élaboration de simvastatine et de ses composés
PL1896364T3 (pl) Proszkowa kompozycja wapna, sposób jej wytwarzania i jej zastosowanie
IL189914A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
WO2007000325A3 (fr) Composes de 1-oxa-3,8-diazaspiro[4.5]-decane-2-one substitues et utilisation de ceux-ci pour produire des medicaments
WO2009121039A3 (fr) Administration de compositions de benzodiazépine
WO2008151273A3 (fr) Systèmes de parfum
WO2006114439A3 (fr) Nouvelles compositions neutraceutiques
WO2007025146A3 (fr) Preparations de balsalazide, leur procede d'obtention et leurs utilisations
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
EP1916251A4 (fr) Sels d érianine, leurs procédés de préparation et compositions pharmaceutiques contenant ceux-ci
WO2010046061A3 (fr) Préparations cosmétiques et/ou pharmaceutiques
WO2006056695A8 (fr) Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
WO2008065282A3 (fr) Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
WO2009035959A3 (fr) Methodes de radiofluoration
WO2008073863A3 (fr) Préparation et utilité d'allylamines substituées
WO2007115929A8 (fr) Thiazolyl-dihydro-quinazolines
WO2006122777A3 (fr) Utilisation de derives de thiazol-4-one 2,5-disubstitues dans des medicaments
WO2008005470A3 (fr) Polypeptides se liant aux protéines de membrane
HK1126190A1 (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880024853.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08805990

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008265021

Country of ref document: AU

Ref document number: 2010511707

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20097026182

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 8177/DELNP/2009

Country of ref document: IN

Ref document number: 2691110

Country of ref document: CA

Ref document number: 2008805990

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008265021

Country of ref document: AU

Date of ref document: 20080612

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0813372

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091215